A silver lining on the horizon for glioblastoma

The Lancet Oncology

Volumn 10, Issue 5, 2009, Pages 434-435

  Knisely, Jonathan P ^a   Baehring, Joachim M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DEATH; DNA METHYLATION; ENZYME INACTIVATION; EPIGENETICS; FOLLOW UP; GLIOBLASTOMA; HUMAN; LETTER; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RISK ASSESSMENT;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; TUMOR SUPPRESSOR PROTEINS;

EID: 65349173566     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70124-X     Document Type: Letter

References (10)

1. Stupp R., Hegi M.E., Mason W.P., et al., on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 (2009) 459-466
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
3. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
4. Cairncross G., and Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 14 (2008) 352-357
5. Radiation Therapy Oncology Group. Radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma or gliosarcoma. http://clinicaltrials.gov/ct2/show/NCT00304031 (accessed Feb 14, 2009).
6. Colman H., and Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 65 (2008) 877-883
7. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 (2009) 740-745
8. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
9. Bristow R.G., and Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8 (2008) 180-192
10. Nicoloso M.S., and Calin G.A. MicroRNA involvement in brain tumors: from bench to bedside. Brain Pathol 18 (2008) 122-129